Biogen receives FDA Breakthrough Therapy Designation for felzartamab in kidney transplant patients.

Biogen has been granted the FDA's Breakthrough Therapy Designation for felzartamab, a treatment targeting antibody-mediated rejection in kidney transplant patients. This designation accelerates the development of therapies showing promise over existing options. Biogen, which acquired the drug from Human Immunology Biosciences in July, plans to begin Phase 3 trials next year for various kidney-related conditions.